Stocks and Investing
Stocks and Investing
Thu, January 25, 2024
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Shagun Singh Reiterated (ABT) at Buy and Held Target at $128 on, Jan 25th, 2024
Shagun Singh of RBC Capital, Reiterated "Abbott Laboratories" (ABT) at Buy and Held Target at $128 on, Jan 25th, 2024.
Shagun has made no other calls on ABT in the last 4 months.
There are 3 other peers that have a rating on ABT. Out of the 3 peers that are also analyzing ABT, 1 agrees with Shagun's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- David Lewis of "Morgan Stanley" Maintained at Hold with Decreased Target to $107 on, Thursday, October 19th, 2023
These are the ratings of the 2 analyists that currently disagree with Shagun
- Lawrence Biegelsen of "Wells Fargo" Maintained at Buy with Increased Target to $121 on, Wednesday, December 13th, 2023
- Matt Miksic of "Barclays" Maintained at Buy with Increased Target to $133 on, Thursday, October 19th, 2023
Contributing Sources